INDAPTUS THERAPEUTICS INC (INDP)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$2.08+12.43%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Manage net losses to avoid worsening financial health: EPS -$0.02 vs target net loss -$8.11M.
Indaptus aims to manage cash flow despite net losses near -$8.11M in 2025-Q4. The company has a strong pipeline in cancer immunotherapy and recently added two independent directors. Operational losses have been persistent but the firm is focused on sustaining operations amid challenges.
The company has lost multiple senior executives including CEO and CFO recently. Net losses are deepening with EPS expected at -$6.43 in 2026 and -$4.48 in 2027. Cash from operations worsened to -$7.01M in 2026-Q1, showing financial strain and uncertain recovery.
The market is selling off sharply with a 43.8% drawdown recently, reflecting concerns about ongoing losses and management instability. There is no clear consensus revenue or EPS growth priced in, and estimates have been revised down over the last 30 days.
Breaks if: additional senior executive resignations occur
Breaks if: net losses worsen beyond -$8.11M in any quarter
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround scenario. The company is currently loss-making and facing elevated risks, but it is also focusing on strategic alternatives and improving its liquidity.
The market seems to have priced in a neutral outlook, reflecting the company's recent financial performance which has improved but remains volatile. There is an expectation of continued challenges given the loss-making status and management's focus on restructuring.
Fundamentals may remain unstable in the near term due to the elevated risk of an earnings miss. Management is actively working on strategic priorities, which could stabilize the situation, but the overall performance remains uncertain.
The long-term thesis hinges on the performance of sector bellwethers like VRTX, REGN, and ARGX, as well as the company's ability to execute its strategic priorities effectively. Any shifts in the broader economic environment, particularly in job growth, could also significantly impact the business.
The most important moves since the prior daily snapshot.
risk label changed from 'elevated' to 'high'.
No, our read on the company is unchanged. The risk label changed from "elevated" to "high". This indicates increased concerns about the company's financial health. Recent financial performance remains steady, but the company is still unprofitable.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Manage cash flow and operating expenses while continuing operations despite ongoing net losses.
Breaks if: cash from operations worsens beyond -$7.01M in any quarter
Manage cash flow and operating expenses while continuing operations despite ongoing net losses.
In the next 1 to 3 years, INDP's performance will depend on both external sector dynamics and internal management execution. Not investment advice.